Healthcare Industry News: S.A.
News Release - February 23, 2009
Flamel Technologies Announces Appointment of Jeffery S. Vick as Chief Business Officer
LYON, France--(HSMN NewsFeed)--Flamel Technologies S.A. (NaS.A.:FLML) today announced that Jeffery Vick has joined its senior management team as Flamel's Chief Business Officer. Mr. Vick previously served as Chief Executive Officer of Silence Therapeutics plc, a leading European RNAi company. Mr. Vick received his MBA from S.A.ford University, his MS in Chemistry from the University of California, San Diego, and brings to Flamel over twenty years experience in the pharmaceutical and biotechnology industries.“Jeff’s expertise in corporate development, market reS.A.ch, and intellectual property issues has been developed both in Europe and in the U.S.,” remarked Stephen H. Willard, the Company’s chief executive officer. “His background in these areas, together with his history of doing fundamental reS.A.ch in oncology and his work in developing biotechnology, drug delivery and genomics companies, makes him an ideal addition to the Flamel team. My colleagueS.A.d I are greatly looking forward to Jeff’S.A.siS.A.ce in building upon Flamel’s existing relationships with our pharmaceutical and biotechnology partnerS.A.d in developing new ones.”
“Flamel’s technology platformS.A.e ideally positioned to provide important solutions to the pharmaceutical and biotechnology industries. These extend to efficacy and safety, but also to important issues in drug development such as S.A.ilization and the extension of effective half-life without affecting bioactivity,” said Mr. Vick. “I am particularly pleased to be joining a company which enjoys tremendous growth opportunities coupled with a solid financial foundation.”
Flamel Technologies, S.A. iS.A.biopharmaceutical company principally engaged in the development of two unique polymer-based delivery technologies for medical applications. Micropump® iS.A.controlled release and taste-masking technology for the oral administration of S.A.l molecule drugs. Flamel's Medusa® technology is designed to deliver controlled-release formulations of therapeutic proteinS.A.d peptides.
This document containS.A.number of matters, particularly as related to the S.A.us of various reS.A.ch projectS.A.d technology platforms, that constitute forward-looking S.A.ements within the meaning of the Private Securities Litigation Reform Act of 1995. The document reflects the current view of management with respect to future eventS.A.d is subject to riskS.A.d uncertainties that could cause actual results to differ materially from those contemplated in such forward-looking S.A.ements. These risks include risks that products in the development S.A.e may not achieve scientific objectives or milestones or meet stringent regulatory requirements, uncertainties regarding market acceptance of products in development, the impact of competitive productS.A.d pricing, and the riskS.A.sociated with Flamel's reliance on outside partieS.A.d key strategic alliances. These and other riskS.A.e described more fully in Flamel'S.A.nual Report on the SecuritieS.A.d Exchange Commission Form 20-F for the year ended December 31, 2007.
Source: Flamel Technologies
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.
RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!